Analysts Lower Expectations for UnitedHealth (UNH) Following Weak Guidance

Core Viewpoint - UnitedHealth Group Incorporated (NYSE:UNH) is experiencing significant challenges, with a notable stock decline and disappointing financial guidance for 2026 [2][3]. Financial Performance - The company reported fourth-quarter results with revenue of $113.2 billion, falling short of the $113.8 billion expected by analysts [3]. - Despite beating earnings estimates by a small margin, the overall sentiment remains negative due to the company's outlook [2][3]. Future Outlook - Management projects full-year 2026 revenue of $439 billion, which is approximately $15 billion lower than Wall Street's expectations [3]. - If this revenue estimate holds, it would represent the company's first annual revenue decline in over 30 years, contributing to the recent stock weakness [3]. Analyst Revisions - Mizuho reduced its price target for UNH from $430 to $350 while maintaining an Outperform rating, citing a slower-than-expected earnings recovery [4]. - Truist analyst David MacDonald lowered the price target from $410 to $370 but kept a Buy rating, reflecting updated estimates following the Q4 results and 2026 guidance [5]. Company Overview - UnitedHealth operates in the healthcare sector with various business lines, including Optum Health, Optum Insight, and Optum Rx, as well as UnitedHealthcare, which serves multiple markets [6].